{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:11:24Z","timestamp":1784196684825,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T00:00:00Z","timestamp":1487203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.seizure.2017.02.008","type":"journal-article","created":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T06:48:01Z","timestamp":1487314081000},"page":"25-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Dosing considerations for rufinamide in patients with Lennox\u2013Gastaut syndrome: Phase III trial results and real-world clinical data"],"prefix":"10.1016","volume":"47","author":[{"given":"Sanjeev","family":"Kothare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Sachdeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Olhaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Perdomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bibbiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2017.02.008_bib0005","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1474-4422(08)70292-8","article-title":"Lennox\u2013Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology","volume":"8","author":"Arzimanoglou","year":"2009","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.seizure.2017.02.008_bib0010","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1177\/08830738020170011001","article-title":"Lennox\u2013Gastaut syndrome","volume":"17","author":"Crumrine","year":"2002","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2017.02.008_bib0015","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/j.1528-1157.1997.tb00065.x","article-title":"Prevalence and descriptive epidemiology of Lennox\u2013Gastaut syndrome among Atlanta children","volume":"38","author":"Trevathan","year":"1997","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"10.1016\/j.seizure.2017.02.008_bib0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/epi.12732","article-title":"The efficacy and tolerability of pharmacologic treatment options for Lennox\u2013Gastaut syndrome","volume":"55","author":"Montouris","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.02.008_bib0025","first-page":"CD003277","article-title":"Treatment of Lennox\u2013Gastaut syndrome","volume":"2","author":"Hancock","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.seizure.2017.02.008_bib0030","author":"BANZEL (rufinamide) Prescribing Information","year":"2015"},{"key":"10.1016\/j.seizure.2017.02.008_bib0035","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1528-1167.2008.01665.x","article-title":"Rufinamide: clinical pharmacokinetics and concentration\u2013response relationships in patients with epilepsy","volume":"49","author":"Perucca","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.02.008_bib0040","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ejpn.2014.05.008","article-title":"Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines","volume":"18","author":"Coppola","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.seizure.2017.02.008_bib0045","author":"Inovelon (rufinamide) tablets and oral suspension Summary of Product Characteristics","year":"2013"},{"key":"10.1016\/j.seizure.2017.02.008_bib0050","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1600-0404.2010.01334.x","article-title":"Adjunctive rufinamide in Lennox\u2013Gastaut syndrome: a long-term, open-label extension study","volume":"122","author":"Kluger","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2017.02.008_bib0055","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1212\/01.wnl.0000303813.95800.0d","article-title":"Rufinamide for generalized seizures associated with Lennox\u2013Gastaut syndrome","volume":"70","author":"Glauser","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2017.02.008_bib0060","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.eplepsyres.2014.08.019","article-title":"Rufinamide as an adjunctive therapy for Lennox\u2013Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan","volume":"108","author":"Ohtsuka","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2017.02.008_bib0065","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.seizure.2010.09.008","article-title":"Rufinamide in children and adults with Lennox\u2013Gastaut syndrome: first Italian multicenter experience","volume":"19","author":"Coppola","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2017.02.008_bib0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.eplepsyres.2009.12.003","article-title":"A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures","volume":"88","author":"Elger","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2017.02.008_bib0075","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10928-009-9146-4","article-title":"Supporting the recommended paediatric dosing regimen for rufinamide in Lennox\u2013Gastaut syndrome using clinical trial simulation","volume":"37","author":"Marchand","year":"2010","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"Suppl 1","key":"10.1016\/j.seizure.2017.02.008_bib0080","first-page":"S27","article-title":"Rufinamide from clinical trials to clinical practice in the United States and Europe","volume":"13","author":"Resnick","year":"2011","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2017.02.008_bib0085","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.eplepsyres.2014.01.013","article-title":"Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders","volume":"108","author":"Cusmai","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2017.02.008_bib0090","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.clineuro.2012.09.021","article-title":"Effectiveness and tolerability of rufinamide in children and young adults with Lennox\u2013Gastaut syndrome: a single center study in Korea","volume":"115","author":"Lee","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.seizure.2017.02.008_bib0095","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eplepsyres.2015.02.003","article-title":"Retention rates of rufinamide in pediatric epilepsy patients with and without Lennox\u2013Gastaut Syndrome","volume":"112","author":"Kessler","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2017.02.008_bib0100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1684\/epd.2011.0406","article-title":"Treatment of malignant migrating partial epilepsy of infancy with rufinamide: report of five cases","volume":"13","author":"Vendrame","year":"2011","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2017.02.008_bib0105","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1528-1167.2010.02729.x","article-title":"A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures","volume":"52","author":"Biton","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.02.008_bib0110","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1055\/s-0032-1324403","article-title":"Rufinamide in children with refractory epilepsy: pharmacokinetics, efficacy, and safety","volume":"43","author":"Dahlin","year":"2012","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.seizure.2017.02.008_bib0115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1756285613481083","article-title":"Efficacy and safety of rufinamide in pediatric epilepsy","volume":"6","author":"Hsieh","year":"2013","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.seizure.2017.02.008_bib0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pediatrneurol.2010.04.003","article-title":"Experience with rufinamide in a pediatric population: a single center's experience","volume":"43","author":"Vendrame","year":"2010","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2017.02.008_bib0125","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ejpn.2014.05.001","article-title":"Efficacy and safety of rufinamide in children under four years of age with drug-resistant epilepsies","volume":"18","author":"Grosso","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.seizure.2017.02.008_bib0130","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.yebeh.2010.11.023","article-title":"Rufinamide for the treatment of epileptic spasms","volume":"20","author":"Olson","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2017.02.008_bib0135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40120-016-0041-9","article-title":"Treatment of adults with Lennox\u2013Gastaut syndrome: further analysis of efficacy and safety\/tolerability of rufinamide","volume":"5","author":"McMurray","year":"2016","journal-title":"Neurol Ther"},{"key":"10.1016\/j.seizure.2017.02.008_bib0140","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/j.1528-1167.2009.02160.x","article-title":"Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial","volume":"50","author":"Brodie","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.02.008_bib0145","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.yebeh.2010.01.005","article-title":"First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy","volume":"17","author":"Kluger","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2017.02.008_bib0150","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.seizure.2012.02.006","article-title":"Rufinamide as an adjuvant treatment in children with Lennox\u2013Gastaut syndrome","volume":"21","author":"Kim","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2017.02.008_bib0155","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.yebeh.2011.04.057","article-title":"Low long-term efficacy and tolerability of add-on rufinamide in patients with Dravet syndrome","volume":"21","author":"Mueller","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2017.02.008_bib0160","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejpn.2011.12.012","article-title":"First long-term experience with the orphan drug rufinamide in children with myoclonic-astatic epilepsy (Doose syndrome)","volume":"16","author":"von Stulpnagel","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.seizure.2017.02.008_bib0165","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.seizure.2012.09.015","article-title":"Rufinamide for refractory focal seizures: an open-label, multicenter European study","volume":"22","author":"Coppola","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2017.02.008_bib0170","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/epi.12689","article-title":"Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience","volume":"55","author":"Thome-Souza","year":"2014","journal-title":"Epilepsia"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131117301267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131117301267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:48:04Z","timestamp":1761011284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131117301267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":34,"alternative-id":["S1059131117301267"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2017.02.008","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosing considerations for rufinamide in patients with Lennox\u2013Gastaut syndrome: Phase III trial results and real-world clinical data","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2017.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}